Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Idera Pharmaceuticals, Inc. (IDRA)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.6000-0.0510 (-7.83%)
At close: 04:00PM EST
0.6099 +0.01 (+1.65%)
After hours: 07:33PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.6510
Open0.6500
Bid0.6000 x 1000
Ask0.6040 x 900
Day's Range0.5911 - 0.6500
52 Week Range0.5900 - 6.1400
Volume657,968
Avg. Volume493,279
Market Cap30.02M
Beta (5Y Monthly)1.60
PE Ratio (TTM)N/A
EPS (TTM)-3.5550
Earnings DateAug 02, 2021 - Aug 06, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.00
  • GlobeNewswire

    Idera Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Update

    EXTON, Pa., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera,” the “Company,” “we,” “us,” or “our”) (Nasdaq: IDRA) today reported its financial and operational results for the third quarter ended September 30, 2021. “We are maintaining our focus on identifying new development or commercial-stage assets for Idera’s portfolio and we are encouraged by the opportunities presented to us,” stated Vincent Milano, Idera’s Chief Executive Officer. “As a number of these prospects adva

  • GlobeNewswire

    Idera Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Update

    EXTON, Pa., Aug. 09, 2021 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera” or the “Company”) (Nasdaq: IDRA) today reported its financial and operational results for the second quarter ended June 30, 2021. “Our goal is to add new development or commercial-stage assets to Idera’s portfolio, and our team is very encouraged by the high quality and quantity of opportunities we have been presented with,” stated Vincent Milano, Idera’s Chief Executive Officer. “Several of these prospects contin

  • Simply Wall St.

    Will Idera Pharmaceuticals (NASDAQ:IDRA) Spend Its Cash Wisely?

    Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Advertisement
Advertisement